Characteristics of Thyrotoxicosis Among Thyroid Patients and their Quality of life in a Teaching Hospital in Jordan: A Crosssectional Study

Main Article Content


Thyrotoxicosis;, Quality of life;, Adherence, Thyroid medications


Aim: This study aimed to describe the general characteristics of thyrotoxicosis patients, evaluate their quality of life and adherence to medications as an outpatient at endocrine clinic in Jordan. Method: This was a descriptive cross-sectional study. The eligible participants, who were patients from endocrine outpatient clinics at JUH were recruited. The inclusion criteria limited the study to patients aged 18 years and older who were newly diagnosed with or had a past diagnosis of hyperthyroidism disease for any cause. Data were analyzed using Statistical Package for Social Sciences version 24.0 (SPSS® Inc., Chicago, IL, USA). Result: Most participants were females (81.3%) and married (87.9%). The majority were educated and had a bachelor’s degree or higher (41.8%). The average reading for T3 was 6.80±8.26 pmol/l, T4 16.87±7.98 pmol/l, TSH 3.49±11.51 Mu/L, Anti thyroglobulin 2.37±1.73, and Anti thyroglobulin peroxidase 4.80±1.13. There were no significant findings in assessing the effect of treatment types on lab tests (p-value >0.05). The majority of thyrotoxicosis cases were caused by Graves’ disease (64.7%), followed by 17.60% from benign multinodular goiter, 11.80% thyroiditis and 5.90% toxic adenoma. There was no significant correlation (p>0.05) between the type of treatments and the following health related quality of life (HRQOL) sub-domains: generally unwell, social problem, muscular skeletal problems, eye problem, classical symptoms of hyperthyroidism(CSH) hand tremor, CSH palpitation, decreased appetite and constipation. Conclusion: Thyrotoxicosis is understudied in the Middle East, particularly Jordan. The main findings revealed that thyrotoxicosis is more prominent in females, mainly in their 4th decade. Future work should focus on the main possible methods to improve the HRQOL. In addition, awareness programs are required to encourage patients to obey the advice of their physician and increase their self-care towards improving the quality of their life.

Abstract 675 | pdf Downloads 643


1. Kim JY, Farmer P, Mark DB, et al. Harrison’s principles of internal medicine. Women’s Health. 2008;39:5.
2. Akamizu T. Thyroid Storm: A Japanese Perspective. Thyroid: official journal of the American Thyroid Association. 2018;28(1):32-40.
3. Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association Guideline for the Management of Graves’Hyperthyroidism. European thyroid journal. 2018;7(4):167-86.
4. Beckett G, MacKenzie F. Thyroid guidelines - are thyroid-stimulating hormone assays fit for purpose? Annals of clinical biochemistry. 2007;44(3):203-8.
5. Vanderpump MP. The epidemiology of thyroid disease. British medical bulletin. 2011;99:39-51.
6. Ajlouni K, Tarwaneh M, El-Khateeb M. Hyperthyroidism in Jordan: A clinical and aetiological review. 1980;1:148-52.
7. Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, et al. The incidence and prevalence of thyroid dysfunction in
Europe: a meta-analysis. The Journal of clinical endocrinology and metabolism. 2014;99(3):923-31.
8. Doubleday AR, Sippel RSJGS. Hyperthyroidism. 2019;9(1):124-35.
9. Abu-Helalah M, Alshraideh HA, Al-Sarayreh SA, et al. A Cross-Sectional Study to Assess the Prevalence of Adult Thyroid
Dysfunction Disorders in Jordan. Thyroid : official journal of the American Thyroid Association. 2019;29(8):1052-9.
10. Lane LC, Cheetham TD, Perros P, et al. New Therapeutic Horizons for Graves’ Hyperthyroidism. Endocrine Reviews.
11. Abdi H, Zakavi SR, Azizi F. A Clinical Debate: What Is the Therapeutic Choice for Recurrent Graves’ Hyperthyroidism? International journal of endocrinology and metabolism. 2020;18(4):e108876.
12. McClung MR, Greer MA. Treatment of hyperthyroidism. Annual review of medicine. 1980;31:385-404.
13. Watt T, Cramon P, Hegedüs L, et al. The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects. The Journal of clinical endocrinology and metabolism. 2014;99(10):3708-17.
14. Watt T, Groenvold M, Rasmussen ÅK, et al. Quality of life in patients with benign thyroid disorders. A review. European Journal of Endocrinology. 2006;154(4):501-10.
15. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical care. 1986;24(1):67-74.
16. Muñoz-Ortiz J, Sierra-Cote MC, Zapata-Bravo E, et al. Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature. Systematic Reviews. 2020;9(1):201.
17. Caputo M, Pecere A, Sarro A, et al. Incidence and prevalence of hyperthyroidism: a population-based study in the Piedmont Region, Italy. Endocrine. 2020;69(1):107-12.
18. Manji N, Carr-Smith JD, Boelaert K, et al. Influences of Age, Gender, Smoking, and Family History on Autoimmune Thyroid Disease Phenotype. The Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4873-80.
19. Al-Geffari M, Ahmad NA, Al-Sharqawi AH, et al. Risk factors for thyroid dysfunction among type 2 diabetic patients in a highly diabetes mellitus prevalent society. 2013.
20. Ismail SI, Mahmoud IS, Al-Ardah M, et al. Detection of combined genomic variants in a Jordanian family with familial nonautoimmune hyperthyroidism. 2009;88(2):233-8.
21. Reid JR, Wheeler SFJAfp. Hyperthyroidism: diagnosis and treatment. 2005;72(4):623-30. 
22. Sundaresh V, Brito JP, Wang Z, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. 2013. 
23. Bianchi G, Zaccheroni V, Solaroli E, et al. Health-related quality of life in patients with thyroid disorders. 2004;13(1):45-54.
24. Klaver EI, van Loon HC, Stienstra R, et al. Thyroid hormone status and health-related quality of life in the LifeLines Cohort Study. 2013;23(9):1066-73.
25. Ladenson PWJCe. Psychological wellbeing in patients. 2002;57(5):575-6.